<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415285</url>
  </required_header>
  <id_info>
    <org_study_id>EU822-03</org_study_id>
    <nct_id>NCT00415285</nct_id>
  </id_info>
  <brief_title>Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia Center for Oncology Research &amp; Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgia Center for Oncology Research &amp; Education</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify new chemotherapy treatment regimens with better&#xD;
      response rates and to find out if the combination of docetaxel and capecitabine can shrink&#xD;
      the size of breast tumors and preserve the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to identify new chemotherapy treatment regimens with better&#xD;
      response rates and to find out if the combination of docetaxel and capecitabine can shrink&#xD;
      the size of breast tumors and preserve the breast.&#xD;
&#xD;
      Induction chemotherapy offers the possibility of less surgery and determines tumor&#xD;
      sensitivity in vivo. Previous trials have demonstrated that complete pathologic response in&#xD;
      the breast at surgery corresponds with improved outcome. Additionally, we will correlate&#xD;
      specific molecular markers in the breast tumors before and after chemotherapy, with response&#xD;
      to treatment.&#xD;
&#xD;
      Expression of these molecular markets may be used in the future to predict the likelihood of&#xD;
      response to chemotherapy given post-operatively.&#xD;
&#xD;
      Approximately 100 patients will participate at Emory Winship Cancer Institute and Emory&#xD;
      Crawford W. Long Hospital and Grady Health System in Atlanta, Georgia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel/Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast carcinoma.&#xD;
&#xD;
          -  Early stage breast cancer (stage 1, 2, 3).&#xD;
&#xD;
          -  No evidence of disease outside the breast or chest wall, except ipsilateral axillary&#xD;
             lymph nodes.&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Final eligibility for a clinical trial is determined by the health professionals&#xD;
             conducting the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast&#xD;
             cancer.&#xD;
&#xD;
          -  Major surgery within 28 days of study entry.&#xD;
&#xD;
          -  Evidence of CNS metastases.&#xD;
&#xD;
          -  Final eligibility for a clinical trial is determined by the health professionals&#xD;
             conducting the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth O'Regan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rita Johnson</last_name>
    <phone>404-778-7777</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Crawford Long Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Johnson</last_name>
      <phone>404-778-7777</phone>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.georgiacore.org</url>
    <description>Georgia Center for Oncology Research and Education</description>
  </link>
  <link>
    <url>http://www.winshipcancerinstitute.org/</url>
    <description>Winship Cancer Institute</description>
  </link>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>February 12, 2007</last_update_submitted>
  <last_update_submitted_qc>February 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2007</last_update_posted>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Early-Stage</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

